The University of Pennsylvania is conducting a Phase 1b open-label study to evaluate CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified recurrent glioblastoma. This study aims to explore different dosing strategies, which could provide a competitive edge in the CAR T-cell therapy market, particularly for glioblastoma, a challenging indication with high unmet medical need. The trial's focus on safety, feasibility, and preliminary efficacy may attract interest from potential partners or investors, especially given the limited treatment options available for recurrent glioblastoma. The successful development of this therapy could position the sponsor favorably in the oncology market, which is increasingly leaning towards personalized and targeted therapies.